| Name | Title | Contact Details |
|---|
Paragon Biosciences invests in and launches biopharmaceutical companies to develop novel therapies for severe medical conditions which do not yet have adequate treatments. Our mission is to help people live longer, healthier lives. Paragon advances that mission through its contribution of Bioscience Innovation Capital(TM): For rare and complex diseases, Paragon analyzes the viability of potential therapies, invests in new biopharmaceutical companies to further develop promising treatments, catalyzes the progress of its portfolio companies through early-incubation services, and provides clinical and regulatory guidance by a team with a near-perfect track record of first-cycle novel drug approvals.
We are working to methodically engineer durable gene therapies for people with devastating diseases.
Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers.
IDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare.
Shasqi develops cancer treatment intended to use bio-orthogonal chemistry for localized drug delivery.